16332-18-6

Basic information

• Product Name: 4-Piperidinol, 4-(4-bromophenyl)-1-(phenylmethyl)-
• Synonyms: 4-(4-bromophenyl)-1-(phenylmethyl)-4-piperidinol;1-Benzyl-4-p-brom-phenyl-piperidinol-(4);1-benzyl-4-(4-bromo-phenyl)-piperidin-4-ol;4-(4-bromophenyl)-1-benzyl-4-hydroxypiperidine;4-Piperidinol,4-(4-bromophenyl)-1-(phenylmethyl)
• CAS NO: 16332-18-6
• Molecular Formula: C18H20BrNO
• Molecular Weight: 346.267
• Mol File: 16332-18-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4-Piperidinol, 4-(4-bromophenyl)-1-(phenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Piperidinol, 4-(4-bromophenyl)-1-(phenylmethyl)-(16332-18-6)
• EPA Substance Registry System: 4-Piperidinol, 4-(4-bromophenyl)-1-(phenylmethyl)-(16332-18-6)

Safety Data

• Hazardous Substances Data: 16332-18-6(Hazardous Substances Data)

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 106-37-6 1.4-dibromobenzene 
• 18620-02-5 (4-bromophenyl)magnesium bromide 
• 100-39-0 benzyl bromide 
• 57988-58-6 4-(4-bromophenyl)-4-hydroxy-piperidine 

Downstream Products

• 403987-56-4 4-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]benzenamine 

Relevant articles and documents

HETEROCYCLIC COMPOUND

The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

Structural changes of benzylether derivatives of vesamicol and their influence on the binding selectivity to the vesicular acetylcholine transporter

18F labelled vesamicol analogues, which bind to the vesicular acetylcholine transporter (VAChT) in central cholinergic nerve terminals, are expected to be potential radioligands for the visualisation of cholinergic transmission deficits via pos

Substituted piperidines - Highly potent renin inhibitors due to induced fit adaptation of tile active site

The identification, synthesis and activity of a novel class of piperidine renin inhibitors is presented. The most active compounds show activities in the picomolar range and are among the most potent renin inhibitors ever identified.